196 related articles for article (PubMed ID: 15126798)
1. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.
Okotie OT; Aronson WJ; Wieder JA; Liao Y; Dorey F; DeKERNION JB; Freedland SJ
J Urol; 2004 Jun; 171(6 Pt 1):2260-4. PubMed ID: 15126798
[TBL] [Abstract][Full Text] [Related]
2. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
Kane CJ; Amling CL; Johnstone PA; Pak N; Lance RS; Thrasher JB; Foley JP; Riffenburgh RH; Moul JW
Urology; 2003 Mar; 61(3):607-11. PubMed ID: 12639656
[TBL] [Abstract][Full Text] [Related]
3. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.
Freedland SJ; Dorey F; Aronson WJ
Urology; 2001 Mar; 57(3):476-80. PubMed ID: 11248623
[TBL] [Abstract][Full Text] [Related]
4. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?
Gomez P; Manoharan M; Kim SS; Soloway MS
BJU Int; 2004 Aug; 94(3):299-302. PubMed ID: 15291855
[TBL] [Abstract][Full Text] [Related]
5. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
6. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
8. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
Patel A; Dorey F; Franklin J; deKernion JB
J Urol; 1997 Oct; 158(4):1441-5. PubMed ID: 9302139
[TBL] [Abstract][Full Text] [Related]
9. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
10. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
11. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
Freedland SJ; Sutter ME; Dorey F; Aronson WJ
Urology; 2003 Feb; 61(2):365-9. PubMed ID: 12597949
[TBL] [Abstract][Full Text] [Related]
12. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
14. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
15. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
Proaño JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
17. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
18. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
19. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
[TBL] [Abstract][Full Text] [Related]
20. Natural history of progression after PSA elevation following radical prostatectomy.
Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
